PURPOSE OF REVIEW: Host genetic factors influencing hepatitis C virus (HCV) transmission outcomes are incompletely defined. However, vast differences observed in rates of spontaneous clearance between individuals infected with the same parental HCV strain strongly indicate a role for genetic determinants in the host immune response to HCV. This review discusses genetic association studies, particularly those published in the last year, that show gene linkages with spontaneous and treatment-induced HCV clearance. The valuable role that blood collection centers can play in increasing the sample size of HCV-confirmed seropositive donors with resolved versus persistent infections for large-scale genetic association studies is highlighted. RECENT FINDINGS: Recent groundbreaking genome-wide association study and targeted single-nucleotide polymorphism (SNP) analysis from independent groups have demonstrated immune response gene polymorphisms, and particularly in the interleukin (IL)-28B gene, that are strongly linked to HCV clearance. The IL-28B gene encodes interferon lambda 3, an innate immune response cytokine. SNPs in the promoter region of IL-28B were first shown to be associated with HCV treatment-induced viral clearance and subsequently to be a key determinant of spontaneous HCV resolution in infected individuals. Samples from blood donors with resolved and chronic HCV infections have contributed to these findings. SUMMARY: These genetic studies have provided the strongest evidence so far of a host genetic determinant linked to HCV clearance. Such large-scale genetic association studies will promote better understanding of HCV disease pathogenesis and assist in effective prognosis of HCV in the future. Continued and preferably expanded participation of blood centers in this research is encouraged.
PURPOSE OF REVIEW: Host genetic factors influencing hepatitis C virus (HCV) transmission outcomes are incompletely defined. However, vast differences observed in rates of spontaneous clearance between individuals infected with the same parental HCV strain strongly indicate a role for genetic determinants in the host immune response to HCV. This review discusses genetic association studies, particularly those published in the last year, that show gene linkages with spontaneous and treatment-induced HCV clearance. The valuable role that blood collection centers can play in increasing the sample size of HCV-confirmed seropositive donors with resolved versus persistent infections for large-scale genetic association studies is highlighted. RECENT FINDINGS: Recent groundbreaking genome-wide association study and targeted single-nucleotide polymorphism (SNP) analysis from independent groups have demonstrated immune response gene polymorphisms, and particularly in the interleukin (IL)-28B gene, that are strongly linked to HCV clearance. The IL-28B gene encodes interferon lambda 3, an innate immune response cytokine. SNPs in the promoter region of IL-28B were first shown to be associated with HCV treatment-induced viral clearance and subsequently to be a key determinant of spontaneous HCV resolution in infected individuals. Samples from blood donors with resolved and chronic HCV infections have contributed to these findings. SUMMARY: These genetic studies have provided the strongest evidence so far of a host genetic determinant linked to HCV clearance. Such large-scale genetic association studies will promote better understanding of HCV disease pathogenesis and assist in effective prognosis of HCV in the future. Continued and preferably expanded participation of blood centers in this research is encouraged.
Authors: Ying Huang; Huiying Yang; Brian B Borg; Xiaowen Su; Shannon L Rhodes; Kai Yang; Xiaomei Tong; George Tang; Charles D Howell; Hugo R Rosen; Chloe L Thio; David L Thomas; Harvey J Alter; Ronda K Sapp; T Jake Liang Journal: Proc Natl Acad Sci U S A Date: 2007-01-10 Impact factor: 11.205
Authors: Nicole E Pagliaccetti; Roger Eduardo; Steven H Kleinstein; Xinmeng Jasmine Mu; Prasanthi Bandi; Michael D Robek Journal: J Biol Chem Date: 2008-08-29 Impact factor: 5.157
Authors: J W Mosley; E A Operskalski; L H Tobler; Z J Buskell; W W Andrews; B Phelps; J Dockter; C Giachetti; L B Seeff; M P Busch Journal: J Viral Hepat Date: 2008-02 Impact factor: 3.728
Authors: Suganya Selvarajah; Sheila Keating; John Heitman; Kai Lu; Graham Simmons; Philip J Norris; Eva Operskalski; James W Mosley; Michael P Busch Journal: J Gen Virol Date: 2012-04-25 Impact factor: 3.891
Authors: Paola Jocelan Scarin Provazzi; Livia Maria Gonçalves Rossi; Bruno Moreira Carneiro; Valeria Chamas Miura; Plinio Cesar Rodrigues Rosa; Lucas Rodrigues de Carvalho; Stephane Tereza Queiroz de Andrade; Roberta Maria Fachini; Rejane Maria Tommasini Grotto; Giovanni Faria Silva; Carlos Roberto Valêncio; Paulo Scarpelini Neto; José Antonio Cordeiro; Mauricio Lacerda Nogueira; Paula Rahal Journal: Braz J Microbiol Date: 2018-12-04 Impact factor: 2.476
Authors: Franziska S Hoffmann; Andreas Schmidt; Meike Dittmann Chevillotte; Christian Wisskirchen; Johannes Hellmuth; Simone Willms; Rachel H Gilmore; Jürgen Glas; Matthias Folwaczny; Tobias Müller; Thomas Berg; Ulrich Spengler; Karen Fitzmaurice; Dermot Kelleher; Nicole Reisch; Charles M Rice; Stefan Endres; Simon Rothenfusser Journal: Hepatology Date: 2015-01-05 Impact factor: 17.425
Authors: Nico Marr; Aaron F Hirschfeld; Angie Lam; Shirley Wang; Pascal M Lavoie; Stuart E Turvey Journal: PLoS One Date: 2014-06-20 Impact factor: 3.240